相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
Laurence Chu et al.
VACCINE (2021)
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Ugur Sahin et al.
NATURE (2021)
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
Antonios O. Aliprantis et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus
Himanshu Garg et al.
SCIENTIFIC REPORTS (2020)
Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose
Eranga Abeyratne et al.
FRONTIERS IN IMMUNOLOGY (2020)
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes A Randomized Clinical Trial
Grace L. Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort
In-Kyu Yoon et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Impact of mRNA chemistry and manufacturing process on innate immune activation
Jennifer Nelson et al.
SCIENCE ADVANCES (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
E. J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The role of IgG Fc receptors in antibody-dependent enhancement
Stylianos Bournazos et al.
NATURE REVIEWS IMMUNOLOGY (2020)
How mRNA therapeutics are entering the monoclonal antibody field
Lien Van Hoecke et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Piotr S. Kowalski et al.
MOLECULAR THERAPY (2019)
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
Robert A Feldman et al.
VACCINE (2019)
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Kimberly J. Hassett et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection
Nurgun Kose et al.
SCIENCE IMMUNOLOGY (2019)
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
Yehuda Z. Cohen et al.
PLOS ONE (2019)
Defining a correlate of protection for chikungunya virus vaccines
Gregg N. Milligan et al.
VACCINE (2019)
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Sabue Mulangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Recent Progress in Vaccine Development Against Chikungunya Virus
Shan Gao et al.
FRONTIERS IN MICROBIOLOGY (2019)
Monoclonal Antibodies for Emerging Infectious Diseases - Borrowing from History
Hilary D. Marston et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
Martin R. Gaudinski et al.
PLOS MEDICINE (2018)
Chikungunya Arthritis Implications of Acute and Chronic Inflammation Mechanisms on Disease Management
Ali Zaid et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Incidence of articular pain and arthritis after chikungunya fever in the Americas: A systematic review of the literature and meta-analysis
Fernando Edington et al.
JOINT BONE SPINE (2018)
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Brinda Emu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial
Emil C. Reisinger et al.
LANCET (2018)
Recent development in the strategies projected for chikungunya vaccine in humans
Manu Goyal et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Vaccine and Therapeutic Options To Control Chikungunya Virus
Ann M. Powers
CLINICAL MICROBIOLOGY REVIEWS (2018)
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
Martin Alberer et al.
LANCET (2017)
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
Christiane R. Stadler et al.
NATURE MEDICINE (2017)
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
Norbert Pardi et al.
NATURE COMMUNICATIONS (2017)
Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques
Rebecca Broeckel et al.
PLOS NEGLECTED TROPICAL DISEASES (2017)
Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen
Jennifer Claydon et al.
PLOS ONE (2017)
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
Moritz Thran et al.
EMBO MOLECULAR MEDICINE (2017)
Modified mRNA Vaccines Protect against Zika Virus Infection (vol 168, pg 1114, 2017)
Justin M. Richner et al.
CELL (2017)
Chikungunya vaccines in development
Michael Schwameis et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus
April M. Clayton
JOURNAL OF INFECTIOUS DISEASES (2016)
Long-Lasting Immune Protection and Other Epidemiological Findings after Chikungunya Emergence in a Cambodian Rural Community, April 2012
Beatriz Galatas et al.
PLOS NEGLECTED TROPICAL DISEASES (2016)
Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus
Scott A. Smith et al.
CELL HOST & MICROBE (2015)
Antibody engineering for increased potency, breadth and half-life
Stuart A. Sievers et al.
CURRENT OPINION IN HIV AND AIDS (2015)
High Rate of Subclinical Chikungunya Virus Infection and Association of Neutralizing Antibody with Protection in a Prospective Cohort in The Philippines
In-Kyu Yoon et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Sung-Youl Ko et al.
NATURE (2014)
Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release
Promsin Masrinoul et al.
VIROLOGY (2014)
Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand
Narong Nitatpattana et al.
VIROLOGY JOURNAL (2014)
Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus
Pankaj Pal et al.
PLOS PATHOGENS (2013)
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein
Yiu-Wing Kam et al.
EMBO MOLECULAR MEDICINE (2012)
Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical Protection
Yiu-Wing Kam et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Prophylaxis and Therapy for Chikungunya Virus Infection
Therese Couderc et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
分享论文
